N/A N=26 Alvimopan and Ileus in PSF
Ileus · Spinal Fusion
Primary: Recovery of Bowel Function — 43.2; 34.0 Hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=112 A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
Ileus · Post-Operative Adhesions
Primary: Change From Baseline in Extent and Severity of Intra-abdominal Adhesions Among Subjects Treated With LB1148 or Placebo — 20.3; 4.3; 4.0; 8.5 total extent and severity…
N/A N=30 Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes
Diabetes
Primary: Percentage of Participants Having Remission of Type 2 Diabetes — 76.66 Percentage of Participants
Phase 4 N=65 Alvimopan as a Rescue Treatment of Postoperative Ileus
Ileus · Gastrointestinal Dysfunction
Primary: Hospital Length of Stay — 5; 6 days
Phase 1 N=41 Chewing Gum Use to Reduce Post-operative Ileus in Pediatric Patients
Post Operative Ileus
Primary: Post-Operative Hospital Stay — 79.93; 72.94 hours — p=0.665
N/A N=203 Optimizing the Previs Device for Prediction of Postoperative Ileus
Ileus
Primary: Device Sensitivity for Predicting Ileus. — 12; 2; 22; 39 Participants
Phase 2 N=402 Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection
Enhanced Recovery After Surgery
Primary: Time to Gastrointestinal Recovery (GIR) — 32.6; 30.8; 33.4 hours — p=0.767
Phase 3 N=524 Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Post-Operative Ileus (POI)
Primary: Time to First Bowel Movement — 4.4; 4.8; 4.6 days — p=0.4259
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
Phase 2 N=82 Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention
Postoperative Ileus
Primary: Time to First Bowel Movement — 61.8; 50.7 hours — p=0.81
N/A N=200 Postoperative Intermittent Intrauterine Balloon Dilatation Therapy.
Intrauterine Adhesion
Primary: Number of Participants With Adhesion Reformation (American Fertility Society Score of Greater Than 0) 8 Weeks Later After the Index Surgery — 21; 38 Participants — p=0.012
Phase 4 N=280 A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy
Postoperative Ileus
Primary: Mean Time to Achieve GI2 Analyzed by Kaplan-Meier (KM) Estimates and Cox Proportional Hazards (PH) Model — 164.2; 132.7 Hours — p=<0.0001
Phase 3 N=374 A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
Ileus
Primary: Time to First Bowel Movement — 93.3; 100.4; 91.3 hours — p=0.944
N/A N=199 S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
Constipation, Impaction, and Bowel Obstruction · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Days Alive and Outside of the Hospital — 42.6; 43.9; 54.8; 52.7 days — p=0.50
N/A N=280 SANICS II Trial: Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition
Postoperative Ileus · Anastomotic Leak
Primary: Number of Patients Developing Postoperative Ileus — 29; 37 Participants
Phase 3 N=146 Accelerating Gastrointestinal Recovery
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Postoperative Length of Hospital Stay — 4.4; 4.3 days — p=0.34
Phase 2 N=428 The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population) — 1.28; 2.12; 2.74; 2.44 CSBMs per week
Phase 2 N=17 Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
Chronic Intestinal Pseudo-obstruction
Primary: Mean Change in Weekly Global Gastrointestinal Symptoms Average Index Score (WGGSAIS). — -0.424; -0.185 score — p==0.1279
Early Phase 1 N=66 Effects of Rocking on Postoperative Ileus Duration Study
Abdominal Cancer
Primary: Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator. — 3.16; 3.88 Days — p=<0.05
Phase 3 N=1,054 The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Number of Overall Responders - ITT Population — 63; 106; 103 Participants
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Phase 4 N=97 Bowel Function After Minimally Invasive Hysterectomy
Constipation
Primary: Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) Score — 1.1; 0.6 score
Phase 2 N=80 Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
Acute Pancreatitis · Intra-abdominal Hypertension
Primary: Percent Change of IAP After Treatment — -18.7; -5.4; -27.2; -20.0 percent change of IAP
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
Phase 4 N=120 Sugammadex To IMprove Bowel Function
Bowel Dysfunction · Postoperative Complications · Neuromuscular Blockade
Primary: Gastric Emptying — 1120; 1130 log(ng*ml-1)*min — p=0.58
N/A N=17 Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction
Duodenal Obstruction
Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants
Phase 2 N=52 Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
Intestinal Obstruction
Primary: Percentage of Responders Before or at Day 7 — 88.2; 25.7; 46.2 percentage of responders — p=0.0055
N/A N=4 Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Constipation-predominant Irritable Bowel Syndrome
Primary: A Change in Length of Spread of Antegrade Contractions After Placebo.
N/A N=84 Effect of Preoperative Fiber on Postoperative Bowel Function
Constipation · Prolapse, Vaginal
Primary: Time to First Bowel Movement After Surgery — 66.5; 68.3 hours
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75